Notice of Preliminary Results

Ergomed

14/02/2023 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230214:nRSN7902Pa&default-theme=true

RNS Number : 7902P  Ergomed plc  14 February 2023

 PRESS RELEASE

 

 

Notice of Preliminary Results

 

 

Guildford, UK - 14 February 2023: Ergomed plc, (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, will announce its preliminary results for the year
ending 31 December 2022 on Tuesday 21 March 2023.

 

Members of the company's Executive Management team including Dr Miroslav
Reljanović (Executive Chairman), Jonathan Curtain (Chief Financial Officer)
and Keith Byrne (SVP, Capital Markets & Strategy) will host an in-person
briefing for analysts at 8.30am GMT on the day of the results at the offices
of Peel Hunt at 100 Liverpool Street, EC2M 2AT. There will also be a live
webcast and conference call with a Q&A session.

 

ENDS

 

Enquiries:

 

 Ergomed plc                                                                 Tel: +44 (0) 1483 402 975
 Miroslav Reljanović (Executive Chairman)
 Jonathan Curtain (Chief Financial Officer)

 Keith Byrne (Senior Vice President, Capital Markets and Strategy)

 Numis (Nominated Adviser and Joint Broker)                                 Tel: +44 (0) 20 7260 1000
 Freddie Barnfield / Euan Brown (Nominated Adviser)
 James Black (Broker)

 Peel Hunt (Joint Broker)                                                   Tel: +44 (0) 20 7418 8900

 James Steel / Dr Christopher
 Golden

 Consilium Strategic Communications - for UK enquiries                      Tel: +44 (0) 20 3709 5700
 Chris Gardner / Matthew Neal                                               ergomed@consilium-comms.com (mailto:ergomed@consilium-comms.com)

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUOSRROSUUAUR